CN112438880A - Fat-reducing therapeutic instrument - Google Patents

Abstract

The utility model provides a fat reducing therapeutic instrument, includes casing (13), vaporization subassembly (1), hose assembly (2), vaporization subassembly (1) is including casing (13), set up high pressure cylinder body subassembly (11) and heating member (113) in casing (13), and its technical essential is: the high-pressure cylinder assembly (11) comprises a first-level high-pressure cavity and a second-level high-pressure cavity which are arranged at the upper part and the lower part and communicated with each other through a first-level electromagnetic valve, a heating body (113) is arranged at the bottom of the first-level high-pressure cavity, a buffer cylinder body (12) is arranged at the side part of the high-pressure cylinder assembly (11), and the buffer cylinder body (12) is communicated with the second-level high-pressure cavity through a; the buffer cylinder body (12) is communicated with the hose assembly (2) through a three-level electromagnetic valve (124). It has the advantages of simple and compact structure, convenient use, easy operation and the like.

Description

Fat-reducing therapeutic instrument

Technical Field

The invention relates to the field of medical appliances, in particular to a lipid-lowering therapeutic apparatus, wherein an IPC main classification number of the lipid-lowering therapeutic apparatus mainly relates to A61H 39/00.

Background

Hyperlipidemia is a condition in which the concentration of one or more components in plasma lipids resulting from disorder of fat metabolism in the human body exceeds the normal upper limit, and may be manifested as hypercholesterolemia, hypertriglyceridemia or both (combined hyperlipidemia). In real life, the number of people with diseases is large, but the attention degree is not enough, and some diseases seriously harming human health, such as atherosclerosis, coronary heart disease, pancreatitis and the like, can be directly caused by improper treatment. The traditional Chinese medicine considers that blood fat is generated by cereals, has the same source with body fluid, is distributed along with the prevalence of body fluid, and exerts normal physiological effects of injecting bones, benefiting marrow, polishing skin and filling body cavities, similar to the modern blood fat thought. If the zang-fu organs are dysfunctional, qi and blood circulation is not smooth, body fluids are not normal, and the disease is caused by qi stagnation, blood stasis, phlegm coagulation and obstruction of meridians.

Hyperlipidemia is one of cardiovascular diseases, and can not only cause fatty liver, but also damage cardiovascular, causing serious cardiovascular problems such as coronary heart disease, arteriosclerosis and the like. Treatment of hyperlipidemia is classified into life treatment, drug treatment, and non-drug treatment. The life treatment is mainly to carry out primary treatment by improving bad life habits and the like, statin lipid-lowering drugs can be selected firstly for the drug treatment of hyperlipidemia, and non-drug treatment is mainly to treat coronary heart disease and the like caused by hyperlipidemia. Changing living habits is a difficult matter to adhere to, and the treatment with drugs has certain damage to the liver and kidney.

Disclosure of Invention

The invention aims to provide a lipid-lowering therapeutic apparatus, which fundamentally solves the problems and has the advantages of simple and compact structure, convenient use, easy operation and the like.

In order to achieve the purpose, the invention provides the following technical scheme: this hypolipidemic therapeutic instrument includes casing, vaporization subassembly, hose assembly, and the vaporization subassembly includes the casing, sets up high-pressure cylinder body subassembly and the heating member in the casing, and its technical essential is: the high-pressure cylinder body assembly comprises a first-stage high-pressure cavity and a second-stage high-pressure cavity which are arranged at the upper part and the lower part and communicated with each other through a first-stage electromagnetic valve, a heating body is arranged at the bottom of the first-stage high-pressure cavity, a buffer cylinder body is arranged at the side part of the high-pressure cylinder body assembly, and the buffer cylinder body is communicated with the second-stage high-pressure; the buffer cylinder body is communicated with the hose assembly through a three-level electromagnetic valve.

Further, hose assembly includes the hose that is linked together through coupling and tertiary solenoid valve and cushion cylinder, sets up the nozzle assembly at the hose tip, and nozzle assembly includes nozzle shell, the jet switch of setting on the casing, the flow control assembly of air conditioning bypass one-level setting at the output.

Further, the liquid medicine in the primary high-pressure cavity is prepared from the following raw materials:

10-20 parts of dried orange peel;

10-20 parts by weight of pinellia ternata;

35-45 parts of bighead atractylodes rhizome;

25-35 parts of poria cocos;

2-6 parts of lotus leaves, 2-6 parts of snakegourd fruits and 2-6 parts of allium macrostemon;

or 2-6 parts of radix bupleuri, 2-6 parts of rheum officinale and 2-6 parts of fleece-flower root slices;

or 2-6 parts by weight of prepared rehmannia root, 2-6 parts by weight of dogwood, 2-6 parts by weight of Chinese yam and 2-6 parts by weight of dodder;

or 2-6 parts of white gourd seed and 2-6 parts of coix seed.

The invention has the beneficial effects that: the high-pressure cylinder body assembly disclosed by the invention adopts the two-stage high-pressure cylinder body and the one-stage buffer cylinder body, and is matched with the three-stage electromagnetic valve to automatically regulate and control the pressure, so that the required steam is continuously output. By arranging the second-stage high-pressure cavity, the sudden change of air pressure caused by the direct communication of the first-stage high-pressure cavity and the atmosphere is avoided. By adopting the secondary high-pressure cavity, when a small amount of high-pressure liquid medicine is communicated with the buffer cylinder body, the liquid medicine is rapidly decompressed and vaporized into liquid medicine steam, the liquid medicine steam is ensured to continuously flow out at a constant speed by matching with the piston of the buffer cylinder body, and the treatment steam with ideal temperature and pressure is output by matching with the adjustable-speed cold air side pipe on the nozzle assembly.

In conclusion, the invention can treat and condition the skin without contacting the skin, is safer and has no side effect. And the Chinese medicine theory is matched, so that the genuine medicinal materials are selected to ensure the curative effect. In the physical therapy process, the medicine is always in a closed environment, so that the loss of effective components is avoided, and the effect of the medicine can be maximally exerted by steam flow of the instrument aiming at the stimulation of specific acupuncture points. Avoids the damage of oral lipid-lowering drugs, such as statins, to the liver.

Drawings

FIG. 1 is a schematic structural diagram of the present invention.

Fig. 2 is a schematic diagram of the operation of the flow regulating assembly of the present invention.

Detailed Description

The present invention will be described in detail with reference to the following embodiments with reference to fig. 1 to 2. The lipid-lowering therapeutic apparatus comprises a shell 13, a vaporization assembly 1, a hose assembly 2 and a control system, wherein the vaporization assembly 1 comprises the shell 13, a high-pressure cylinder assembly 11 arranged in the shell 13 and a heating body 113. The high-pressure cylinder assembly 11 comprises a primary high-pressure cavity 111 and a secondary high-pressure cavity 112 which are arranged at the upper part and the lower part and communicated with each other through a primary electromagnetic valve, a heating body 113 is arranged at the bottom of the primary high-pressure cavity 111, a buffer cylinder 12 is arranged at the side part of the high-pressure cylinder assembly 11, and the buffer cylinder 12 is communicated with the secondary high-pressure cavity through a secondary electromagnetic valve; the cushion cylinder 12 communicates with the hose assembly 2 through a three-stage solenoid valve 124. A driving gear 121, a rack 122 meshed with the driving gear 121 and a piston 123 arranged at the bottom of the rack 122 are arranged in the buffer cylinder 12 through a driving motor; the drive gear 121 is a half-tooth gear; the cushion cylinder 12 communicates with the hose assembly 2 through a three-stage solenoid valve 124. A heat insulating layer 131 is provided between the high pressure cylinder assembly 11 and the housing 13, and the high pressure cylinder assembly 11 is sealed by a sealing cover 132. A filter screen 111b is arranged in the first-stage high-pressure cavity 111, the filter screen 111b can be used for containing required medicinal materials, and the pretreated liquid medicine can be directly placed in the first-stage high-pressure cavity 111.

The control system comprises a processor module, a signal input module and a signal receiving module. The signal input module comprises a pressure sensor I (not shown in the figure) arranged in the primary high-pressure cavity 111, a temperature sensor I, a pressure sensor II (not shown in the figure) arranged in the secondary high-pressure cavity 112, a pressure sensor III (not shown in the figure) arranged in the buffer cylinder body, a temperature sensor II arranged in the nozzle assembly 22, and a display screen 221 arranged on the outer wall of the nozzle assembly shell.

The receiving module comprises a heating circuit, a first-stage electromagnetic valve 111a, a second-stage electromagnetic valve 112a, a third-stage electromagnetic valve 124 and a driving motor on the buffer cylinder.

The hose assembly 2 comprises a hose 21 communicated with the buffer cylinder through a pipe joint and a three-stage solenoid valve 124, a nozzle assembly 22 arranged at the end part of the hose 21, wherein the nozzle assembly 22 comprises a nozzle shell 13, a spray switch 222 arranged on the shell 13, a cold air bypass pipe 23 and a flow regulating assembly 223 arranged at the output end of the nozzle shell 13. The flow regulating assembly 223 comprises a plurality of vanes 223a and an adjusting ring 223b which are arranged along the circumferential direction, each vane 223a is hinged on the adjusting ring 223b through a fixing column 223e at equal intervals, and the outer side of each vane 223a is limited in a limiting groove 223c on the inner side of the nozzle shell 13 through a limiting column 223 d. During the use, can drive the adjustable ring 223b rotatory through the knob on the rotatory nozzle casing 13, and then drive blade 223a and swing on spacing post 223d and fixed column 223e two point positions, and then the size in adjustment center exhaust hole.

The rack gear 122 and the piston 123 are driven to reciprocate in the cushion cylinder 12 by the driving gear 121 through unidirectional rotation of an output shaft provided to a driving motor (not shown). Thereby adjusting the used volume of the cushion cylinder 12 (the lower region of the piston 123). Assuming that the displacement of the piston in the vertical direction when the gear is at the position in fig. 1 is 0, the gear angle and rack displacement correspondence relationship is as shown in the following table.

TABLE 1 correspondence between gear rotation angle a and rack displacement d

Note: when the rack is positioned at the top, the displacement is Ymax, and the buffer cylinder body has the maximum volume Vmax;

when the rack is positioned at the lowest part, the displacement is-Ymax, and the buffer cylinder body has the minimum volume Vmin.

The working process of cooperation between each cavity and the solenoid valve is detailed by taking the P1 threshold value of 5atm (boiling point of 151.1 ℃) as an example. Meanwhile, the maximum pressure which can be borne by the high-pressure cylinder assembly 11 is 10 atm-15 atm due to the comprehensive consideration of the factors such as safety, manufacturing cost, cylinder volume and cylinder weight (the larger the bearing force is, the thicker the cylinder side wall is). Of course, in order to prolong the service time of the equipment, the threshold value and the bearing capacity of the cylinder body can be correspondingly improved.

For convenience of presentation, the pressure of the first stage high pressure chamber 111 is denoted as P1, the liquid temperature therein is denoted as T1, the gas temperature within the nozzle assembly is denoted as T2, the first stage solenoid valve is denoted as v1, the pressure of the second stage high pressure chamber 112 is denoted as P2, the second stage solenoid valve is denoted as v2, the pressure of the cushion cylinder is denoted as P3, the third stage solenoid valve is denoted as v3, the heating circuit is denoted as H, and the atmospheric pressure is denoted as P0.

TABLE 2 corresponding relationship between signal input module and signal receiving module under different states

State I: p1<5atm, P2< <5atm, P3= P0, and T1<150 ℃, the heating circuit is connected, and v 1-v 3 are closed.

In addition, the protection circuit is arranged on the heating body 113, and no matter in any state, when the threshold value T1 is greater than T1 within a certain range, such as the threshold value T1 is higher than the threshold value T20-50 ℃, the heating circuit stops working when the liquid in the primary high-pressure cavity is not enough, so that the 'dry burning' in the primary high-pressure cavity is avoided, and the service life of components is shortened.

And state II: p1 is approximately equal to 5atm, P2 is less than 5atm, P3= P0, and T1 is approximately equal to 150 ℃, the heating circuit is closed, v1 is opened, v 2-v 3 is closed, and the liquid medicine in the primary high-pressure cavity enters the secondary high-pressure cavity under the action of gravity.

And state III: p1 ≈ 5atm, P2 ≈ 5atm, P3= P0, and when T1 ≈ 150 ℃, v 1-v 3 are closed, and the secondary high-pressure cavity 112 is filled with the liquid medicine.

The second-stage high-pressure chamber 112 is much smaller in volume than the first-stage high-pressure chamber 111, and since there is only a small amount of liquid, the liquid medicine lost each time does not have a significant effect on P1. Upon a sudden pressure drop in the secondary high pressure chamber 112 (in communication with the cushion cylinder 12), all of the liquid in the secondary high pressure chamber 112 is rapidly vaporized without bumping. By arranging the second-stage high-pressure cavity 112, overlarge air pressure change amplitude caused by direct communication between the first-stage high-pressure cavity 111 and the atmosphere can be avoided, and the safety is further improved.

And state IV: v1 is closed, v2 is opened, v3 is closed, the liquid medicine in the secondary high-pressure cavity is rapidly vaporized and the buffer cylinder is filled, and at the moment, P1 is approximately equal to 5atm, and P0< P2= P3<5 atm.

And a state V: when the pressure of P3 reaches the P3 threshold value, v3 is opened, and physiotherapy can be performed by controlling the injection switch 222 and the flow regulating assembly 223.

Set up temperature sensor (not shown in the figure) in the hose assembly 2, press the jet switch 222 of hose assembly 2, tertiary solenoid valve 124 opens, steam gets into hose assembly 2 through buffer cylinder 12, and mix with hose assembly 2's bypass cooling gas, the temperature sensor that sets up in hose assembly 2 detects the temperature of gas in the hose 21, when the temperature reaches the setting value, the valve on the nozzle 22 can be opened and spout steam, and set up red green pilot lamp, when T2 satisfied the setting temperature, then the pilot lamp is green, thereby avoid scalding. By setting the flow rate of the bypass cooling gas (since the P3 threshold is constant, the bypass flow rate control device is the mixer temperature control device), the temperature of the mixed vapor finally discharged from the nozzle 22 can be set.

When the pressure in the hose assembly is reduced along with the use process, v2 and v3 are simultaneously opened to gradually vaporize the liquid medicine in the P2, and in order to avoid the overlarge P2 and P3, the volume of the buffer cylinder body can be adjusted through the driving motor in the buffer cylinder body, and then P2 and P3 are adjusted.

When P2 is smaller than the P2 threshold, v1 is opened, v2 is closed, v3 is opened, the state II and the state III are repeated, and the liquid medicine is filled in the second-level high-pressure cavity again. In order to avoid temporary pressure loss in the hose caused by v2 closing, the driving motor of the buffer cylinder body drives the piston to move to contract the volume of the buffer cylinder body so as to realize the buffer effect, and in the buffer process, the secondary high-pressure cavity is filled with the liquid medicine again, so that the pressure of P3 can be continuously maintained. Therefore, the liquid medicine in the primary high-pressure cavity can be safely and stably converted into steam flow with constant pressure and constant temperature.

Meanwhile, in order to explain the safety of the high-pressure cylinder and the comparison relationship between the heat capacity and the pressure of the liquid medicine, the following table is provided. The production standard for liquefied gas tanks is in accordance with GB17267-1998, up to 2.1MPa (about 20 atm). The high-pressure cylinder body assembly of the embodiment not only has a volume far smaller than that of the liquefied gas tank, but also has relatively small bearing capacity, and completely meets the safety requirements in production and use. It can be seen that for every 1atm increase in the P1 threshold, the amount of heat carried by the same volume of liquid medicine increases by about 10%.

By combining the control method, the whole therapeutic apparatus can be automatically controlled by an embedded programming or programmable processor (the threshold value is automatically set according to different conditions). The operating parameters of P1-P3 and T1-T2 and the working state of H can be output to the display screen in real time through the processor module, so that the use is convenient.

TABLE 3 comparison of boiling points of water under different pressure conditions

For the treatment of hyperlipidemia, the solution in the primary hyperbaric chamber can adopt the following formula:

main drugs:

10-20 parts of dried orange peel

10-20 parts by weight of pinellia ternata

35-45 parts of bighead atractylodes rhizome

25-35 parts by weight of poria cocos

Adjuvant drugs:

the sputum is heavy, and 2-6 parts by weight of lotus leaves, 2-6 parts by weight of snakegourd fruits and 2-6 parts by weight of longstamen onion bulbs are matched;

the traditional Chinese medicine composition is prepared from 2-6 parts by weight of radix bupleuri, 2-6 parts by weight of rheum officinale and 2-6 parts by weight of polygonum multiflorum tablets, wherein the severe blood stasis syndrome is severe;

2-6 parts of prepared rhizome of rehmannia, 2-6 parts of dogwood, 2-6 parts of yam and 2-6 parts of dodder when the deficiency syndrome is severe;

the traditional Chinese medicine composition is mainly used for treating damp type, and is matched with 2-6 parts by weight of white gourd seeds and 2-6 parts by weight of coix seeds.

According to the differentiation of the traditional Chinese medicine, appropriate acupuncture points are selected. The therapeutic head of the lipid-lowering therapeutic apparatus was placed about 1cm above the selected acupuncture point, and the patient was asked to calm and relax. And starting the machine after the time intensity is set. Different time gears and previous gears can be selected according to the disease condition degree, and the gear can be larger for the more serious disease condition.

Selecting acupoints for treating excessive phlegm syndrome: fenglong, Zhongwan, Tianshu, and meat sliding door

Selection of acupoints with predominant blood stasis: door with functions of grain, water, hinge and meat sliding

Selection of acupoints for predominant deficiency syndrome: qihai, Guanyuan, Sanyinjiao, Zusanli and Zhongwan

The heavy type of damp disease selects acupoints: zhongwan, Tianshu, moisture, Qihai, and Tilia

Hyperlipidemia is a condition in which the concentration of one or more components in plasma lipids resulting from disorder of fat metabolism in the human body exceeds the normal upper limit, and may be manifested as hypercholesterolemia, hypertriglyceridemia or both (combined hyperlipidemia). The traditional Chinese medicine considers that blood fat is generated by cereals, has the same source with body fluid, is distributed along with the prevalence of body fluid, and exerts normal physiological effects of injecting bones, benefiting marrow, polishing skin and filling body cavities, similar to the modern blood fat thought. If the zang-fu organs are dysfunctional, qi and blood circulation is not smooth, body fluids are not normal, and the disease is caused by qi stagnation, blood stasis, phlegm coagulation and obstruction of meridians. Therefore, this method selects Chen Pi, Bai Zhu and Fu Ling as main drugs, which can help the spleen and stomach to transport and transform, and ban Xia to help dispel the stubborn phlegm for the purpose of enhancing the efficacy.

Case 1:

mr. Zhang, 32 years old, the workplace sold elite in white collar, and was rewarded with a lot of remuneration on a regular day. Dyslipidemia was found in 3 months physical examination in 2017, and Total Cholesterol (TC) was 5.67mmol/L, Triglyceride (TG) was 1.89mmol/L, High Density Lipoprotein (HDL) was 1.23mmol/L, and Low Density Lipoprotein (LDL) was 2.53 mmol/L. The traditional Chinese medicine composition has no other uncomfortable symptoms, no history of diseases such as hypertension, diabetes, fatty liver and the like, and no history of drug allergy. The clinical diagnosis is hyperlipidemia (mixed type), and 40mg/d qn of atorvastatin calcium tablets are recommended to be orally taken and rechecked after one week. Patients refused oral medication, diet by themselves and exercise intervention, and blood-related indexes are reviewed after one month: 5.62mmol/L of Total Cholesterol (TC), 1.78mmol/L of Triglyceride (TG), 1.32mmol/L of high-density lipoprotein (HDL), 2.4mmol/L of low-density lipoprotein (LDL), no obvious improvement of blood lipid index (no obvious abnormality is found in other blood biochemical tests), and then the inventor enters groups for observation. Intervention was given to the lipid lowering device (1 time a day, 1 hour each time), and regular work and rest, diet, and appropriate exercise were ordered to maintain good lifestyle habits. On day 13 of intervention by the lipid-lowering instrument, the subject consciously had clear mind and good comfort, had no obvious change in blood pressure, blood sugar and body weight, and was instructed to adhere to the cooperative treatment without blood biochemical examination. On the 25 th day of intervention of the lipid-lowering instrument, the patient is recommended to go to a hospital to review blood lipid related biochemical examination, wherein TC 4.7mmol/L, TG 1.27mmol/L, HDL 1.32mmol/L and LDL 2.17mmol/L are shown in the blood lipid result, all indexes are normal, and no abnormality is found in the biochemical examination.

Case 2:

mr. Zhang, age 21, student, mild obesity, love to eat fried food in peace of mind, are demented in online games, do not like sports. Hospital examination finds: blood pressure 138/85mmHg, fasting blood glucose 6.7 mmol/L; the blood biochemical examination result shows that: 5.83mmol/L of Total Cholesterol (TC), 1.98mmol/L of Triglyceride (TG), 1.17mmol/L of high-density lipoprotein (HDL), 2.03mmol/L of low-density lipoprotein (LDL), 87g/L of total serum protein, 55g/L of serum albumin, 78U/L of alanine Aminotransferase (ALT) and 92U/L of aspartate Aminotransferase (AST); alkaline phosphatase (ALP), gamma-transpeptidase (gamma-GT), and serum bilirubin (STB, CB, UCB) were not found to be abnormal. The history of fatty liver is 1 year, and the history of hypertension, diabetes and other diseases and the history of drug allergy are not existed. The group is observed in 2019 in 1 month, the lipid-lowering instrument is given 1 time a day, 1 hour of intervention is performed every time, the patient is ordered to eat light diet and make regular work and rest, and the patient appropriately participates in physical activities. After the intervention of a lipid-lowering instrument for 20 days, a subject has no obvious uncomfortable performance and no change of body abnormity, but has good self-complaint sleep, refreshing after sleeping, 130/70mmHg of blood pressure, 6.3mmol/L of random blood sugar and no biochemical examination of blood circulation. On day 42 of lipid lowering device intervention, biochemical examination of blood circulation in hospital shows: 5.7mmol/L of fasting blood glucose, 5.03mmol/L of Total Cholesterol (TC), 1.38mmol/L of Triglyceride (TG), 1.37mmol/L of High Density Lipoprotein (HDL), 1.97mmol/L of Low Density Lipoprotein (LDL), 48U/L of glutamic-pyruvic transaminase (ALT) and 50U/L of glutamic-oxalacetic transaminase (AST), and no obvious abnormality is found in the residue biochemical examination. The intervention of the lipid-lowering instrument is performed 1 time a day, 1 hour each time, and the related blood biochemical examination is reviewed in the hospital at the 90 th day, no obvious abnormality is seen, and the intervention treatment of the lipid-lowering instrument is stopped.

Case 3:

zhao women, 57 years old, 3 years old with hypertension history, smooth control with 5mg Bid blood pressure 130/70mmHg, 1 year old with coronary heart disease and atherosclerosis history, 20mg isosorbide mononitrate oral on weekdays, 0.1g aspirin maintenance therapy. The clinical diagnosis of hyperlipemia is carried out after more than 3 years of dyslipidemia, and the treatment is not intervened by medicine on a daily basis. No history of other diseases such as heart failure, diabetes, tumor and the like, and no history of drug allergy. The patient feels tired and weak, is easy to sweat and likes to sleep in a conscious day, but the sleep quality is not good enough (dreaminess). 2016, 10 months of group observation, and the prompt of blood fat index inspection in hospitals: total Cholesterol (TC) 6.67mmol/L, Triglyceride (TG) 2.89mmol/L, High Density Lipoprotein (HDL) 1.07mmol/L, Low Density Lipoprotein (LDL) 2.0 mmol/L. The patient was given a lipid lowering device intervention (1-2 times daily, 1 hour each time) with the original medication unchanged, ordered his low salt and low fat diet, and paid attention to regular diet and sleep. On the 20 th day of group observation, the subject consciously had a clear head and relaxed body, had gradually improved sleep, no fluctuation in blood pressure, and no manifestation of cardiac discomfort. Order to adhere to lipid lowering device intervention (1 time a day, 1 hour each). On the 55 th day of group observation, the subject goes to the hospital for blood biochemical examination, and the blood lipid examination shows that various indexes of the patient are obviously reduced, and the specific results are as follows: total Cholesterol (TC) 5.31mmol/L, Triglyceride (TG) 2.3mmol/L, High Density Lipoprotein (HDL) 1.07mmol/L, Low Density Lipoprotein (LDL) 1.6 mmol/L.

Case 4:

mr. Yang, age 54, coronary heart disease (stable angina) and hyperlipemia history 5 years, oral Beibai aspirin and simvastatin 20mg/d on weekday. The blood lipid index of the hospital is high after years of reexamination: 5.7mmol/L of Total Cholesterol (TC), 2.6mmol/L of Triglyceride (TG), 1.37mmol/L of High Density Lipoprotein (HDL), 2.1mmol/L of Low Density Lipoprotein (LDL), and no obvious abnormality of other blood biochemical indexes. After group observation, the blood fat reducing instrument is used for intervention once a day, 1 hour is carried out each time, and the blood fat is clinically rechecked after 30 days. The biochemical indexes of blood show that: total Cholesterol (TC) 5.2mmol/L, Triglyceride (TG) 1.9mmol/L, High Density Lipoprotein (HDL) 1.41mmol/L, and Low Density Lipoprotein (LDL) 1.7 mmol/L. After the intervention of the lipid-lowering instrument for 60 days, the biochemical indexes of clinical rechecking blood show that the blood fat recovers to the normal level: 4.8mmol/L of Total Cholesterol (TC), 1.5mmol/L of Triglyceride (TG), 1.4mmol/L of High Density Lipoprotein (HDL), and 1.6mmol/L of Low Density Lipoprotein (LDL). During the intervention period of the lipid-lowering instrument, patients have no angina attack and no other body discomfort phenomenon.

207 cases of subjects are cumulatively collected in the base station during 2015-2019, the total effective rate of the intervention of the lipid-lowering instrument reaches 99.8%, and the average intervention time is 63 days (10 days as a treatment course). The method provides wider research and exploration opportunities for treating patients with hyperlipidemia, improves the treatment of hyperlipidemia to a new height, and deserves larger-scale subjects to participate in observation and statistical analysis.

Description of reference numerals:

1 vaporization assembly

11 high-pressure cylinder body assembly

111 primary high pressure cavity

111a primary electromagnetic valve

111b sieve

112 two-stage high-pressure cavity

112a two-stage solenoid valve

113 heating body

12 buffer cylinder

121 drive gear

122 rack

123 piston

124 three-stage solenoid valve

13 casing

131 heat insulation layer

132 sealing cover

2 hose assembly

21 flexible pipe

22 nozzle assembly

221 display screen

222 jetting switch

223 flow regulating assembly

223a blade

223b adjusting ring

223c limiting groove

223d limiting column

223e fixed column

23 cold air side pipe

Claims (2)

1. The utility model provides a fat reducing therapeutic instrument, includes casing (13), vaporization subassembly (1), hose assembly (2), vaporization subassembly (1) including casing (13), set up high pressure cylinder body subassembly (11) and heating member (113) in casing (13), its characterized in that: the high-pressure cylinder assembly (11) comprises a first-level high-pressure cavity and a second-level high-pressure cavity which are arranged at the upper part and the lower part and communicated with each other through a first-level electromagnetic valve, a heating body (113) is arranged at the bottom of the first-level high-pressure cavity, a buffer cylinder body (12) is arranged at the side part of the high-pressure cylinder assembly (11), and the buffer cylinder body (12) is communicated with the second-level high-pressure cavity through a; a driving gear 121, a rack 122 meshed with the driving gear 121 and a piston 123 arranged at the bottom of the rack 122 are arranged in the buffer cylinder 12 through a driving motor; the drive gear 121 is a half-tooth gear; the buffer cylinder body (12) is communicated with the hose assembly (2) through a three-level electromagnetic valve (124);

the hose assembly (2) comprises a hose (21) communicated with the buffer cylinder through a pipe joint and a three-stage electromagnetic valve (124) and a nozzle assembly (22) arranged at the end part of the hose (21), wherein the nozzle assembly (22) comprises a nozzle shell (13), a spray switch (222) arranged on the shell (13) and a flow regulating assembly (223) arranged at the output end of the cold air bypass pipe (23) in a one-stage mode.

2. The lipid-lowering therapeutic apparatus according to claim 1 or 2, wherein the liquid medicine in the primary high-pressure chamber is prepared from the following raw materials:

10-20 parts of dried orange peel;

10-20 parts by weight of pinellia ternata;

35-45 parts of bighead atractylodes rhizome;

25-35 parts of poria cocos;

2-6 parts of lotus leaves, 2-6 parts of snakegourd fruits and 2-6 parts of allium macrostemon;

or 2-6 parts of radix bupleuri, 2-6 parts of rheum officinale and 2-6 parts of fleece-flower root slices;

or 2-6 parts by weight of prepared rehmannia root, 2-6 parts by weight of dogwood, 2-6 parts by weight of Chinese yam and 2-6 parts by weight of dodder;

or 2-6 parts of white gourd seed and 2-6 parts of coix seed.

Images